Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.

Alphatec Holdings, a medical technology company specialising in spinal surgery solutions, reported strong first-quarter 2026 results with surgical revenue up 17% and total revenue growing 14% to $192 million. The company achieved non-GAAP adjusted EBITDA of $21 million whilst securing a new bank facility that reduces annual interest expenses by over $6 million. Growth was driven by a 21% increase in surgical case volume and 23% rise in net new surgeon users. The company reported an ending cash balance of $140 million and trailing twelve-month free cash flow of $7 million. For full-year 2026, Alphatec expects total revenue of approximately $882 million, representing 15% growth, with adjusted EBITDA projected at $134 million and at least $20 million in free cash flow generation.

Kirby McInerney LLP is investigating potential securities law violations by Alphatec Holdings and its senior management following a sharp share price decline. On 5 May 2026, Alphatec reported first quarter revenue of $192 million and disclosed that EOS revenue, from its proprietary imaging platform, was $14 million—below internal expectations. The company reduced its full-year 2026 EOS revenue guidance to approximately $77 million from $85 million, citing execution issues with equipment installations. Management stated that "installation timing was a challenge" and the company failed to fulfill committed units. Following the announcement, Alphatec shares fell 32%, from $10.23 to $6.99 per share. No lawsuit has been filed yet, and the investigation is ongoing to determine whether claims may be brought under federal securities laws.